The effect of symptom-relieving drugs are beneficial in Alzheimer's disease;Värt ge symtomlindrande läkemedel vid Alzheimers sjukdom

Lakartidningen

Volumn 103, Issue 6, 2006, Pages 369-371

  Nordberg, Agneta ^a   Eriksdotter Jönhagen, Maria ^a   Garlind, Anita ^b   Grut, Michaela ^c   Freund Levi, Yvonne ^a   Cornelius, Christel ^a   Ekström, Anna ^d   Fastbom, Johan ^e   Sedvall, Marie ^f   Viitanen, Matti ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Södra Stockholms Geriatriska Klinik   (Sweden)

^c DANDERYD HOSPITAL   (Sweden)

^d STOCKHOLM SÖDER HOSPITAL   (Sweden)

^e AGING RESEARCH CENTER   (Sweden)

^f Husläkarmottagningen Bennedich and Björk ^*  (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR;

ALZHEIMER DISEASE; DISEASE COURSE; HUMAN; QUALITY OF LIFE; REVIEW; RISK FACTOR;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DISEASE PROGRESSION; HUMANS; QUALITY OF LIFE; RISK FACTORS;

EID: 33645010624     PISSN: 00237205     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Gustafson L, Brun A. [Alzheimer disease - soon a hundred-year-old history]. Läkartidningen 2004;101:4125-6, 4129-32.
2. Braak H, Braak E. Diagnostic criteria for neuropathologic assessment of Alzheimer's disease. Neurobiol Aging 1997;18:S85-8.
3. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, Ausen B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Langstrom B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306-19.
4. Nordberg A. PET imaging of amyloid in Alzheimer's disease. Lancet Neurol 2004;3:519-27.
5. Mattson MP. Pathways towards and away from Alzheimer's disease. Nature 2004;430:631-9.
6. Francis P, Nordberg A, Arnold S. A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease? Trends in Pharmacological Science 2005;26:104-111.
7. Nordberg A. The effect of cholinesterase inhibitors studied with brain imaging. In: Giacobini E, editor. Cholinesterase and Cholinesterase inhibitors. London: Martin Dunitz; 2000. p. 237-247.
8. Nordberg A, Stefanova E, Darreh-Shori T, Wall A. Butyrylcolinesterase, studies with brain imaging. In: Giacobini E, editor. Butyrcholinesterase: its function and its inhibitors. London: Martin Dunitz; 2003. p. 91-100.
9. Stefanova E, Blennow K, Almkvist O, Hellstrom-Lindahl E, Nordberg A. Cerebral glucose metabolism, cerebrospinal fluid-beta-amyloid1-42 (CSF-Abeta42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients. Neurosci Lett 2003;338:159-63.
10. Stefanova E, Wall A, Almkvist O, Nilsson A, Forsberg A, Långström B, Nordberg A. Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer's disease. J Neural Transm 2005;(in press; Epub ahead of print).
11. LV. Farmakologisk behandling av kognitiv störning vid Alzheimers sjukdom. Information från Läkemedelsverket 7/8 2002.
12. Doraiswamy PM. The role of the N-methyl-D-aspartate receptor in Alzheimer's disease: therapeutic potential. Curr Neurol Neurosci Rep 2003;3:373-8.
13. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. Jama 2004;291:317-24.
14. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000;54:2261-8.
15. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001;57:613-20.
16. Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, Pratt RD. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001;57:481-8.
17. Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, Wetterholm AL, Zhang R, Haglund A, Subbiah P. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001;57:489-95.
18. Loy C, Schneider L. Galantamine for Alzheimer's disease. Cochrane Database Syst Rev 2004:CD001747.
19. Birks J, Grimley Evans J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev 2000:CD001191.
20. Birks JS, Harvey R. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 2003:CD001190.
21. Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, Edwards S, Hardyman W, Raftery J, Crome P, Lendon C, Shaw H, Bentham P. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004;363:2105-15.
22. Rainer M, Mucke HA, Kruger-Rainer C, Kraxberger E, Haushofer M, Jellinger KA. Cognitive relapse after discontinuation of drug therapy in Alzheimer's disease: cholinesterase inhibitors versus nootropics. J Neural Transm 2001;108:1327-33.
23. Cummings JL. Alzheimer's disease. N Engl J Med 2004;351:56-67.
24. Etminan M, Gill S, Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. Bmj 2003;327:128.
25. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. Bmj 2001;322:1447-51.
26. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003;61:46-54.